Bernhard Winkler, Associate Professor Priv. Doz. DDR.

Dr. Bernhard Winkler, Associate Professor Priv. Doz. DDR.


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
DFDeborah Fusco
Deborah Fusco
FMFlorian Meissner
Florian Meissner
BPBruno K. Podesser
Bruno K. Podesser
AMAnna Marsano
Anna Marsano
MGMartin Grapow
Martin Grapow
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.
Surgical revascularization is the gold standard in most cases of complex coronary artery disease. For coronary artery bypass grafting, autologous grafts are state-of-the-art due to their long-term patency. A non-negligible amount of patients lack suitable bypass material as a result of concomitant diseases or previous interventions. As a promising alternative, tissue-engineered vascular grafts made of biomaterials such as bacterial cellulose (BC) are gaining more and more attention. However, the production of small-diameter grafts (inner diameter < 6 mm) of application-oriented length (> 5 cm) and their in vivo long-term patency remain challenging. In this study, grafts of 20 cm in length with an inner diameter of 3 mm were generated in a custom-made bioreactor. To potentially improve graft compliance and, therefore in vivo patency, BC was combined with an embedded cobalt–chromium mesh. The grafts were designed for in vivo endothelialization and specific surgical properties and implanted as an aortocoronary bypass in a left anterior descending occluded pig model (n = 8). Coronary angiography showed complete patency postoperatively at 4 weeks. Following 4 weeks in vivo, the grafts were explanted revealing a three-layered wall structure. Grafts were colonized by smooth muscle cells and a luminal layer of endothelial cells with early formation of vasa privata indicating functional remodeling. These encouraging findings in a large animal model reveal the great potential of small-diameter BC grafts for coronary and peripheral bypass grafting.

27 February 2024 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
MEMaximilian Y. Emmert
Maximilian Y. Emmert
JBJohannes Bonatti
Johannes Bonatti
ECEtem Caliskan
Etem Caliskan
MGMario Gaudino
Mario Gaudino
MGMartin Grabenwöger
Martin Grabenwöger
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.
Coronary artery bypass grafting (CABG) is and continues to be the preferred revascularization strategy in patients with multivessel disease. Graft selection has been shown to influence the outcomes following CABG. During the last almost 60 years saphenous vein grafts (SVG) together with the internal mammary artery have become the standard of care for patients undergoing CABG surgery. While there is little doubt about the benefits, the patency rates are constantly under debate. Despite its acknowledged limitations in terms of long-term patency due to intimal hyperplasia, the saphenous vein is still the most often used graft. Although reendothelialization occurs early postoperatively, the process of intimal hyperplasia remains irreversible. This is due in part to the persistence of high shear forces, the chronic localized inflammatory response, and the partial dysfunctionality of the regenerated endothelium. “No-Touch” harvesting techniques, specific storage solutions, pressure controlled graft flushing and external stenting are important and established methods aiming to overcome the process of intimal hyperplasia at different time levels. Still despite the known evidence these methods are not standard everywhere. The use of arterial grafts is another strategy to address the inferior SVG patency rates and to perform CABG with total arterial revascularization. Composite grafting, pharmacological agents as well as latest minimal invasive techniques aim in the same direction. To give guide and set standards all graft related topics for CABG are presented in this expert opinion document on graft treatment.

15 October 2020 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
MMMarkus Mach
Markus Mach
VWVictoria Watzal
Victoria Watzal
WHWaseem Hasan
Waseem Hasan
MAMartin Andreas
Martin Andreas
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.
MGMartin Grabenwöger
Martin Grabenwöger
Background: While transcatheter aortic valve replacement (TAVR) has revolutionized the treatment of aortic valve stenosis, wearable health-monitoring devices are gradually transforming digital patient care. Objective: The aim of this study was to develop a simple, efficient, and economical method for preprocedural frailty assessment based on parameters measured by a wearable health-monitoring device. Methods: In this prospective study, we analyzed data of 50 consecutive patients with mean (SD) age of 77.5 (5.1) years and a median (IQR) European system for cardiac operative risk evaluation (EuroSCORE) II of 3.3 (4.1) undergoing either transfemoral or transapical TAVR between 2017 and 2018. Every patient was fitted with a wrist-worn health-monitoring device (Garmin Vivosmart 3) for 1 week prior to the procedure. Twenty different parameters were measured, and threshold levels for the 3 most predictive categories (ie, step count, heart rate, and preprocedural stress) were calculated. Patients were assigned 1 point per category for exceeding the cut-off value and were then classified into 4 stages (no, borderline, moderate, and severe frailty). Furthermore, the FItness-tracker assisted Frailty-Assessment Score (FIFA score) was compared with the scores of the preprocedural gait speed category derived from the 6-minute walk test (GSC-6MWT) and the Edmonton Frail Scale classification (EFS-C). The primary study endpoint was hospital mortality. Results: The overall preprocedural stress level (P=.02), minutes of high stress per day (P=.02), minutes of rest per day (P=.045), and daily heart rate maximum (P=.048) as single parameters were the strongest predictors of hospital mortality. When comparing the different frailty scores, the FIFA score demonstrated the greatest predictive power for hospital mortality (FIFA area under the curve [AUC] 0.844, CI 0.656-1.000; P=.048; GSC-6MWT AUC 0.671, CI 0.487-0.855; P=.42; EFS-C AUC 0.636, CI 0.254-1.000; P=.44). Conclusions: This proof-of-concept study demonstrates the strong predictive performance of the FIFA score compared to that of the conventional frailty assessments.

28 October 2022 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
AKAttila Kiss
Attila Kiss
PSPetra Lujza Szabo
Petra Lujza Szabo
CDChristopher Dostal
Christopher Dostal
ZAZsuzsanna Arnold
Zsuzsanna Arnold
DGDaniela Geisler
Daniela Geisler
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.
Background: Saline is still the most widely used storage and rinsing solution for vessel grafts during cardiac surgery despite knowing evidence of its negative influence on the human endothelial cell function. Aim of this study was to assess the effect of DuraGraft©, an intraoperative graft treatment solution, on human saphenous vein segments and further elaborate the vasoprotective effect on rat aortic segments in comparison to saline. Methods: Human Saphenous vein (HSV) graft segments from patients undergoing aortocoronary bypass surgery (n = 15), were randomized to DuraGraft© (n = 15) or saline (n = 15) solution before intraoperative storage. Each segment was divided into two subsegmental parts for evaluation. These segments as well as rat aortic segments stored in DuraGraft© underwent assessment of vascular function in a multichamber isometric myograph system in comparison to Krebs-Henseleit solution (KHS), a physiologic organ buffer solution. Results: Potassium-Chloride (KCL)-induced contraction depicted a tendency towards increase when treated with DuraGraft© compared to saline preservation of HSV segments (23.02 ± 14.77 vs 14.44 ± 9.13 mN, p = 0.0571). Vein segments preserved with DuraGraft© showed a significant improvement of endothelium-dependent vasorelaxation in response to cumulative concentrations of bradykinin compared to saline treated segments (p < 0.05). Rat aortic segments stored in saline showed significantly impaired vasoconstriction (3.59 ± 4.20, p < 0.0001) and vasorelaxation when compared to KHS and DuraGraft© (p < 0.0001). Conclusions: DuraGraft© demonstrated a favorable effect on graft relaxation and contraction indicating preservation of vascular endothelial function. Clinical Trial Registration Number: NCT04614077.

13 June 2021 in European Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
MMMarkus Mach
Markus Mach
VWVictoria Watzal
Victoria Watzal
CCCarina Cuhaj
Carina Cuhaj
WHWaseem Hasan
Waseem Hasan
TPThomas Poschner
Thomas Poschner
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.

1 July 2015 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
BMBernhard Meier
Bernhard Meier
BDBernhard Winkler, Associate Professor Priv. Doz. DDR.
Bernhard Winkler, Associate Professor Priv. Doz. DDR.
TCThierry Pierre Carrel
Thierry Pierre Carrel
Christoph HuberChristoph Huber
Christoph Huber